BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24582269)

  • 1. Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?
    Martinez P; Martinez-Marti A; Navarro A; Cedrés S; Felip E
    Lung Cancer; 2014 May; 84(2):97-100. PubMed ID: 24582269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted agents in non-small cell lung cancer (NSCLC): clinical developments and rationale for the combination with thoracic radiotherapy.
    Koh PK; Faivre-Finn C; Blackhall FH; De Ruysscher D
    Cancer Treat Rev; 2012 Oct; 38(6):626-40. PubMed ID: 22196919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy for surgically resected non-small cell lung cancer.
    Heon S; Johnson BE
    J Thorac Cardiovasc Surg; 2012 Sep; 144(3):S39-42. PubMed ID: 22502967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triplet chemotherapy combinations with new agents: is there a rationale?
    Bunn PA
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):55-61. PubMed ID: 9728586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant treatment of resected nonsmall cell lung cancer: state of the art and new potential developments.
    Felip E; Martinez-Marti A; Martinez P; Cedres S; Navarro A
    Curr Opin Oncol; 2013 Mar; 25(2):115-20. PubMed ID: 23262832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
    Alden RS; Mandrekar SJ; Oxnard GR
    Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of novel second-line targeted therapies in non-small cell lung cancer.
    Massarelli E; Herbst RS
    Semin Oncol; 2006 Feb; 33(1 Suppl 1):S9-16. PubMed ID: 16472704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
    Patel JD; Pasche B; Argiris A
    Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
    Rossi A; Pasquale R; Esposito C; Normanno N
    Cancer Treat Rev; 2013 Aug; 39(5):489-97. PubMed ID: 23022519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C
    Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant radiotherapy and chemotherapy for stage II or IIIA non-small-cell lung cancer after complete resection. Provincial Lung Cancer Disease Site Group.
    Logan DM; Lochrin CA; Darling G; Eady A; Newman TE; Evans WK
    Cancer Prev Control; 1997 Dec; 1(5):366-78. PubMed ID: 9765759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 13. Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
    Roengvoraphoj M; Tsongalis GJ; Dragnev KH; Rigas JR
    Cancer Treat Rev; 2013 Dec; 39(8):839-50. PubMed ID: 23768755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update.
    Mendoza L
    Klin Onkol; 2009; 22(4):131-8. PubMed ID: 19731875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
    Hirsch FR
    Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy for non-small-cell lung carcinoma: from a blanket approach to individual therapy.
    Reungwetwattana T; Eadens MJ; Molina JR
    Semin Respir Crit Care Med; 2011 Feb; 32(1):78-93. PubMed ID: 21500127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.
    Gridelli C; Massarelli E; Maione P; Rossi A; Herbst RS; Onn A; Ciardiello F
    Cancer; 2004 Oct; 101(8):1733-44. PubMed ID: 15386339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
    Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
    J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.